← All candidates
Two insider buys in the last year — $78.8K in all.
31 filings on record.
KRROKorro Bio, Inc.
NasdaqCM · Healthcare · $207.19M
$14.07
+1.37% · Sep 15
Two insider buys in the last year — $78.8K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys● 21 sells◆ 2 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what KRRO ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$207.19M
Float
10.5M
71% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
87.0
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Lynx1 Capital Management LP
Bought $59.5K on Aug 6 — 5,222 sh @ $11.40, held indirect, 0.3% of their stake.
2 of 4 positions beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
24 more transactions on Pro →Context
Wall St
$20.20 avg target
+43.6% vs today · 10 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 5 quarters beat
Q2 '26−$1.07 act+$0.21
Q1 '26−$1.69 act+$0.29
Q4 '25−$1.65 act+$0.49
Q3 '25−$1.92 act+$0.76
Coverage
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?Zacks · 06-19One Korro Bio Insider Raised Stake By 19% In Previous YearSimply Wall St. · 06-11What Makes Korro Bio, Inc. (KRRO) a New Buy StockZacks · 04-28Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue EstimatesZacks · 03-12
The file stays open
31 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice